ReviewCancer chemotherapy and pharmacology2025
Clinical pharmacology and therapeutic applications of talazoparib: a comprehensive review.
Review in Cancer chemotherapy and pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival.Oncology research · 2026Observational
- PARP inhibitor BMN673 triggers PARylation-mediated ATF4-GDF15 pathway to drive autophagy and ferroptosis in ataxia telangiectasia mutated gene-deficient colorectal cancer cells.Molecular biomedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis review seeks to offer an in-depth assessment of talazoparib, a highly effective PARP inhibitor, and its clinical uses in oncology. There is a special focus on pharmacokinetics, pharmacodynamics, safety, drug interaction, and licensed therapeutic uses, in addition to the incorporation of mechanistic data pertinent to its effectiveness. The purpose is to assist clinicians through clinical data.
methodsThe available literature was widely searched to identify studies between 2010 and 2024 using keywords such as “Talazoparib”, “Clinical Trials”, “PARP inhibitor”, and “treatment efficacy”. Both clinical and pre-clinical data were reviewed primarily from randomized controlled trials, observational studies, peer-reviewed articles, meta-analyses and clinical trial databases.
resultsThe US Food and Drug Administration initially approved talazoparib, one of the most effective polyadenosine diphosphate ribose inhibitors, in October 2018 based on the phase-3 EMBRACA trial. It is preferred for HER-2 negative BRCA1/2 breast malignancies and for local castration-resistant prostate cancer (when combined with enzalutamide) due to its high efficacy with exposure and dynamic nature. Recent and current trials on talazoparib for the treatment of several neoplastic disorders, including ovarian cancer, have shown results warranting further clinical investigation.
conclusionTalazoparib has shown robust efficacy in BRCA1/2-mutated tumors and is already used in breast cancer and prostate cancer. It is being investigated in other solid tumors but its clinical application in those settings is still under investigation. Several challenges remain, such as the development of PARPi resistance. Its therapeutic use may expand through continuing clinical studies, particularly when used with other chemotherapeutic drugs.
Indexed as
Identifiers
40956449What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.